- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Report
- January 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3284EUR$3,750USD£2,851GBP
- Report
- July 2024
- 150 Pages
Global
From €3284EUR$3,750USD£2,851GBP
- Report
- April 2023
- 125 Pages
Global
From €4160EUR$4,750USD£3,611GBP
Combigan is a brand name for a combination of two drugs, brimonidine and timolol, used to treat glaucoma and other optical disorders. It is a topical ophthalmic solution that is applied directly to the eye. The drug works by reducing the pressure in the eye, which can help prevent further damage to the optic nerve. It is often prescribed in combination with other medications to treat glaucoma and other optical disorders.
The Combigan market is a competitive one, with several companies offering similar products. Some of the major players in the market include Allergan, Bausch + Lomb, Merck, and Pfizer. Other companies such as Novartis, Sun Pharma, and Santen Pharmaceuticals also offer products in this market. Show Less Read more